Eine Phase 1/2a Dosis Eskalations- und Kohorten Expansions-Studie um die Sicherheit, Verträglichkeit und Wirksamkeit von BMS-986156 als Monotherapie oder in Kombination mit Nivolumab (BMS-936558, anti PD-1 monoklonaler Antikörper) bei Patienten mit fortgeschrittenen soliden Tumoren zu untersuchen

Drug: BMS-986156;Drug: Nivolumab

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- For Dose Escalation:

- Subjects with any previously treated advanced (metastatic or refractory) solid
tumor

- For Cohort Expansion:

- Subjects must have a previously treated advanced solid tumor to be eligible

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy

- Women of child-bearing potential and men must use an acceptable method of
contraception during treatment and for 23 weeks after treatment for women and 31 weeks
for men

Exclusion Criteria:

- Known central nervous system metastases or central nervous system as the only source
of disease

- Other concomitant malignancies (with some exceptions per protocol)

- Active, known or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

- History of active or chronic hepatitis (e.g. Hep B or C)

- Impaired liver or bone marrow function

- Major surgery less than 1 month before start of the study